CA-EV-CONNECT
21.5.2024 12:01:29 CEST | Business Wire | Press release
With 5.7 million electric vehicles (EVs) anticipated to be used in fleet applications by 2025, EV Connect, a leading EV charging business platform, and bp pulse, a global leader in charging infrastructure for fleets and public charging, today announced a collaboration to bring key capabilities of Omega, bp pulse's EV charge management software, to the EV Connect platform. Tailored to the diverse charging requirements and duty cycles of EV fleets, Omega delivers a comprehensive managed charging solution that integrates state-of-the-art charging management technology from EV Connect and bp pulse into a new, comprehensive fleet offering.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240521725993/en/
The collaboration gives fleet operators greater control over charging infrastructure while reducing costs associated with energy consumption and providing detailed historical data for further optimization. (Graphic: Business Wire)
With bp pulse and EV Connect’s Omega integration, fleet operators can focus on their core business while Omega orchestrates charging schedules, prioritizes charging based on fleet needs, and enables real-time insights for informed decision-making, whether charging at depots, on the go, or at driver homes. The collaboration between bp pulse and EV Connect gives fleet operators greater control over charging infrastructure while reducing costs associated with energy consumption and providing detailed historical data for further optimization.
"At bp pulse, we remain steadfast in our mission to simplify electrification for diverse fleets, and collaborating with EV Connect on this endeavor marks an exciting milestone, expanding our scope to deliver turnkey solutions for fleet operators industry-wide," said Sujay Sharma, CEO of bp pulse Americas. “Our shared goal is to provide fleet customers with a comprehensive solution that addresses all aspects of their charging needs—no matter the location. This collaboration allows us to combine our unique offerings into one cohesive platform."
Omega orchestrates EV charging to optimize cost-effective charging for fleets, while the EV Connect platform focuses on managing financial transactions, particularly in commercial fleet settings. This includes fleet operations in which drivers bring vehicles home, requiring private chargers with simple reimbursement options. By combining the capabilities of Omega and the EV Connect platform, fleet operators, including those in government, municipal, logistics, services, and sales sectors, can expect improved efficiency and optimization of their charging stations while empowering fleet managers with precise control over when and how their vehicles are charged, optimizing for factors like energy cost, power constraints, vehicle readiness, and operational efficiency.
"This collaboration between EV Connect and bp pulse brings unparalleled expertise in the electric vehicle charging industry, opening doors to elevate our fleet management capabilities and deliver cutting-edge solutions that set new standards for both of our customers," said Jon Leicester, Vice President and Head of Commercial at EV Connect. "By integrating our platforms, we can offer a comprehensive management solution that caters to fleet operators looking to optimize electric fleet efficiency like never before."
EV Connect is the conduit to accelerating EV charging business growth with technology and tools that drive innovation to fuel new business models in e-mobility. To learn more about how EV Connect is helping businesses of all sizes unlock the power of EV charging business models, please visit www.evconnect.com.
About EV Connect
EV Connect is the all-in-one EV charging platform that delivers the tools to build, run, and scale EV charging businesses successfully. The platform serves a broad set of use cases for customers, including Charge Point Operators (CPOs), charging network providers, Fortune 500 companies, charging business upstarts and trailblazers, fleet-scale transportation providers, and electric utilities.
EV Connect customers benefit from a combination of cutting-edge software features with premium service experiences, such as branded customer support, EV charging station procurement, deployment and installation support, and the latest driver app technology. Because technology, public policy, and technical standards constantly evolve and change, EV Connect has built its platform and tools to ensure that an investment in electric vehicle charging equipment delivers exceptionally reliable performance, confidence in station utilization and revenue management, and return on investment. Founded in 2010, EV Connect offers the tools and connections for EV charging businesses of any size, with the power of an open-platform approach and a trusted partner network.
For more information, please visit www.evconnect.com and follow us on X and LinkedIn.
About bp pulse
bp pulse is bp’s electric vehicle (EV) charging business, rolling out fast, reliable charge points to consumers and commercial fleets around the world. Globally, bp pulse is one of the UK’s leading rapid and ultra-fast public EV charging networks. It also operates the largest number of sites with ultra-fast charging in Germany, with a growing charging point footprint in China and the Netherlands. The company aims to increase its network of public EV charging points by 2030 to over 100,000 worldwide.
bp pulse is bp’s electric vehicle (EV) charging business. Focused on fast and reliable charging, bp pulse deploys charging points for EV drivers and commercial fleets on the go; at destination hubs, at the depot and bp retail sites. Around the world bp pulse is working with some of the world’s biggest businesses, while developing the Gigahub™ network, a series of large EV high-speed charging hubs in high-demand locations. Electric vehicle charging is one of five growth engines of bp’s transformation into an integrated energy company. The company has already installed more than 27,000 charge points and aims to expand its network of public EV charging stations to more than 100,000 worldwide by 2030. In the US, bp is planning to invest up to $1 billion in EV charging by 2030. For more information, visit bppulsefleet.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521725993/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom